Novavax Inc. [NASDAQ: NVAX] price surged by 1.94 percent to reach at $3.17. The company report on October 5, 2021 that Novavax Announces Leadership Appointment and Updates.
– Denny Kim, M.D. appointed Senior Vice President, Chief Safety Officer.
– Raburn Mallory, M.D. promoted to Senior Vice President, Head of Clinical Development.
A sum of 4434958 shares traded at recent session while its average daily volume was at 5.04M shares. Novavax Inc. shares reached a high of $173.24 and dropped to a low of $163.71 until finishing in the latest session at $166.39.
The one-year NVAX stock forecast points to a potential upside of 37.02. The average equity rating for NVAX stock is currently 2.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Novavax Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $264.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 12, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on December 14, 2020, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another raise from $132 to $290, while H.C. Wainwright kept a Buy rating on NVAX stock.
The Average True Range (ATR) for Novavax Inc. is set at 15.38, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 10.59. The Price to Book ratio for the last quarter was 16.54, with the Price to Cash per share for the same quarter was set at 27.58. Price to Free Cash Flow for NVAX in the course of the last twelve months was 21.12 with Quick ratio for the last quarter at 1.40.
NVAX Stock Performance Analysis:
Novavax Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.78. With this latest performance, NVAX shares dropped by -28.98% in over the last four-week period, additionally sinking by -17.67% over the last 6 months – not to mention a rise of 41.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 33.07, with the RSI for the last a single of trading hit 28.97, and the three-weeks RSI is set at 37.32 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 223.12, while it was recorded at 164.95 for the last single week of trading, and 198.35 for the last 200 days.
Insight into Novavax Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -87.05. Novavax Inc.’s Net Margin is presently recorded at -87.94.
Return on Total Capital for NVAX is now -65.98, given the latest momentum, and Return on Invested Capital for the company is -73.12. Return on Equity for this stock declined to -189.60, with Return on Assets sitting at -47.65. When it comes to the capital structure of this company, Novavax Inc. [NVAX] has a Total Debt to Total Equity ratio set at 76.83. Additionally, NVAX Total Debt to Total Capital is recorded at 43.45, with Total Debt to Total Assets ending up at 30.45. Long-Term Debt to Equity for the company is recorded at 59.35, with the Long-Term Debt to Total Capital now at 33.56.
Reflecting on the efficiency of the workforce at the company, Novavax Inc. [NVAX] managed to generate an average of -$528,772 per employee. Receivables Turnover for the company is 3.53 with a Total Asset Turnover recorded at a value of 0.54.Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
NVAX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.
Novavax Inc. [NVAX] Insider Position Details
There are presently around $6,630 million, or 55.30% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 6,670,660, which is approximately 13.19% of the company’s market cap and around 0.30% of the total institutional ownership; FMR LLC, holding 4,885,203 shares of the stock with an approximate value of $812.85 million in NVAX stocks shares; and BLACKROCK INC., currently with $757.98 million in NVAX stock with ownership of nearly -16.766% of the company’s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 235 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 5,774,668 shares. Additionally, 187 investors decreased positions by around 8,043,951 shares, while 66 investors held positions by with 26,028,343 shares. The mentioned changes placed institutional holdings at 39,846,962 shares, according to the latest SEC report filing. NVAX stock had 100 new institutional investments in for a total of 1,568,845 shares, while 83 institutional investors sold positions of 1,823,951 shares during the same period.